Nothing Special   »   [go: up one dir, main page]

CY1121436T1 - Δοσολογια για τους αναστολεις των kinασων janus (jak) - Google Patents

Δοσολογια για τους αναστολεις των kinασων janus (jak)

Info

Publication number
CY1121436T1
CY1121436T1 CY20191100203T CY191100203T CY1121436T1 CY 1121436 T1 CY1121436 T1 CY 1121436T1 CY 20191100203 T CY20191100203 T CY 20191100203T CY 191100203 T CY191100203 T CY 191100203T CY 1121436 T1 CY1121436 T1 CY 1121436T1
Authority
CY
Cyprus
Prior art keywords
jak
mammal
janus
inhibitors
dosage
Prior art date
Application number
CY20191100203T
Other languages
English (en)
Inventor
Andrea J. GONZALES
Sallie B. COSGROVE
Phyllis B. MALPAS
Michael Rolf STEGEMANN
Wendy Turner COLLARD
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY1121436T1 publication Critical patent/CY1121436T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μία μέθοδο για την θεραπεία της αλλεργικής δερματίτιδας, της ατοπικής δερματίτιδας ή ενός ή περισσοτέρων συμπτωμάτων τους, σε θηλαστικό που την έχει ανάγκη, η οποία μέθοδος περιλαμβάνει την χορήγηση στο θηλαστικό μίας πρώτης, θεραπευτικά αποτελεσματικής δόσης ενός αναστολέα κινάσης Janus (JAK), δύο φορές την ημέρα, για μία περίοδο ημερών επαρκών ώστε να μειωθούν ή να εξαλειφθούν ένα ή περισσότερα κλινικά συμπτώματα στο θηλαστικό, ακολουθούμενη από μία δεύτερη θεραπευτικά αποτελεσματική δόση του ανασταλτικού παράγοντα JAK, με μειωμένη όμως συχνότητα.
CY20191100203T 2012-07-20 2019-02-14 Δοσολογια για τους αναστολεις των kinασων janus (jak) CY1121436T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
CY1121436T1 true CY1121436T1 (el) 2020-05-29

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100203T CY1121436T1 (el) 2012-07-20 2019-02-14 Δοσολογια για τους αναστολεις των kinασων janus (jak)

Country Status (24)

Country Link
US (1) US9522151B2 (el)
EP (1) EP2874630B1 (el)
JP (2) JP6022063B2 (el)
KR (2) KR20150028299A (el)
CN (2) CN108354938A (el)
AU (1) AU2013292547B2 (el)
BR (1) BR112015000808A2 (el)
CA (1) CA2878867C (el)
CY (1) CY1121436T1 (el)
DK (1) DK2874630T3 (el)
ES (1) ES2707627T3 (el)
HK (2) HK1209314A1 (el)
HR (1) HRP20182088T1 (el)
HU (1) HUE042771T2 (el)
IN (1) IN2015DN00370A (el)
LT (1) LT2874630T (el)
MX (1) MX360857B (el)
NZ (1) NZ703152A (el)
PL (1) PL2874630T3 (el)
PT (1) PT2874630T (el)
RS (1) RS58242B1 (el)
SI (1) SI2874630T1 (el)
WO (1) WO2014015107A1 (el)
ZA (1) ZA201500134B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2958921T3 (pl) 2013-02-22 2018-01-31 Pfizer Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinaz janusowych (jak)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
MX2018004605A (es) 2015-10-16 2018-11-29 Abbvie Inc Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP7096592B2 (ja) * 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Ｊａｋ阻害剤およびこれらの利用
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
BR112021014525A8 (pt) * 2019-01-30 2022-11-22 Gargamel Zhuhai Biotech Ltd Inibidor de jak e método de preparação do mesmo
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CA3201608A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
MX2011001904A (es) 2008-08-20 2011-03-29 Pfizer Compuestos de pirrolo[2,3-d]pirimidina.

Also Published As

Publication number Publication date
JP2015522620A (ja) 2015-08-06
LT2874630T (lt) 2019-02-11
HUE042771T2 (hu) 2019-07-29
NZ703152A (en) 2016-03-31
PT2874630T (pt) 2019-01-31
IN2015DN00370A (el) 2015-06-12
US9522151B2 (en) 2016-12-20
US20150126535A1 (en) 2015-05-07
HK1209314A1 (en) 2016-04-01
MX360857B (es) 2018-11-20
AU2013292547A1 (en) 2015-01-22
CN108354938A (zh) 2018-08-03
KR20170034949A (ko) 2017-03-29
RS58242B1 (sr) 2019-03-29
ZA201500134B (en) 2016-08-31
AU2013292547B2 (en) 2017-05-04
SI2874630T1 (sl) 2019-04-30
PL2874630T3 (pl) 2019-04-30
ES2707627T3 (es) 2019-04-04
CA2878867A1 (en) 2014-01-23
HK1252083A1 (zh) 2019-05-17
DK2874630T3 (en) 2019-01-28
KR20150028299A (ko) 2015-03-13
JP6022063B2 (ja) 2016-11-09
MX2015000871A (es) 2015-05-07
HRP20182088T1 (hr) 2019-02-08
EP2874630A1 (en) 2015-05-27
JP2017019816A (ja) 2017-01-26
BR112015000808A2 (pt) 2017-06-27
EP2874630B1 (en) 2018-12-05
WO2014015107A1 (en) 2014-01-23
CA2878867C (en) 2018-01-09
CN104470525A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
CY1121436T1 (el) Δοσολογια για τους αναστολεις των kinασων janus (jak)
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1125436T1 (el) Αναστολεις dna-pk
CY1123631T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
EA201500362A1 (ru) Ингибиторы rho-киназы
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201591509A1 (ru) Ингибиторы cdc7
EA201490545A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201490925A1 (ru) Ингибиторы pak для лечения синдрома умственной отсталости, сцепленного с ломкой х хромосомой
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ